安罗替尼联合阿霉素和异环磷酰胺治疗软组织肉瘤肺转移的疗效及安全性分析

目的：回顾性研究阿霉素和异环磷酰胺（adriamycin ifosfamide,AI）方案化疗联合安罗替尼维持治疗对软组织肉瘤肺转移患者的疗效与安全性。方法：收集天津医科大学肿瘤医院2018年6月至2022年4月软组织肉瘤肺转移接受AI方案化疗联合安罗替尼维持性治疗的32例患者。按照实体瘤疗效评价标准RECIST 1.1进行治疗效果评价，计算客观缓解率（objective response rate,ORR）及疾病控制率（disease control rate,DCR），统计分析中位无进展生存期（median progression-free survival,mPFS）、中位总生存期（median overall survival,mOS）及相关不良事件。结果：32例软组织肉瘤肺转移患者中完全缓解（complete response,CR）1例（3.1%）,部分缓解（partial response,PR）10例（31.2%）,病情稳定（stable disease,SD）9例（28.1%），疾病进展（progress disease,PD）12例（37.5%）,ORR为34.3%...

Efficacy and safety of anlotinib combined with adriamycin ifosfamide in the treatment of lung metastasis of soft tissue sarcoma

  Objective  To retrospectively study the efficacy and safety of adriamycin ifosfamide (AI) combined with anlotinib maintenance therapy in patients with lung metastasis of soft tissue sarcoma.   Methods  Patients with lung metastasis of soft tissue sarcoma treated in the tumor hospital of Tianjin Medical University from June 2018 to April 2022 were collected. They received AI and anlotinib maintenance treatment. The treatment effect was evaluated according to the solid tumor efficacy evaluation standard (RECIST) 1.1, the objective response rate (ORR) and disease control rate (DCR) were calculated, and the median progression-free survival (mPFS), median overall survival (mOS) and related adverse events were statistically analyzed.   Results  A total of 32 patients with lung metastasis of soft tissue sarcoma were included. One patient achieved complete response (CR) (3.1%), and 10 had partial response (PR) (31.2%), 9 had stable disease (SD) (28.1%), 12 had progress disease (PD) (37.5%); ORR was 34.3%, DCR was 62.5%. The mPFS was 6.0 months and mOS was 15.0 months. The treatment-related adverse events of most patients were grade 1-2. Grade 3-4 adverse events included pleural effusion (n=2, 6.25%), anemia (n=5, 15.6%), leucopenia (n=4, 12.5%). Grade 5 adverse events were pneumothorax (n=1, 3.1%).   Conclusions  AI combined with anlotinib maintenance therapy has a certain effect on patients with lung metastasis of soft tissue sarcoma. Most patients can tolerate the adverse events, which can be used as an effective treatment for lung metastasis of soft tissue sarcoma.